| HOME >> MEDICINE >> TECHNOLOGY |
- Entrance of Big Pharma into contract manufacturing
- Vertical integration with CROs
- Emergence of specialty CMO players
- Risk sharing programs
•Restraints inhibiting greater CMO usage
- Pharma industry consolidation
- Lack of specialized manufacturing capacity
- Manufacturing budget reductions
- Heightened regulatory scrutiny
- CMO personnel shortages
- CMO alternatives
•Conclusion
Continued demand in the established regions
•Summary
•Introduction
•The US CMO market
- Overview
- US CMO usage by segment, 2011–2017
•The Western European CRO market
- Overview
- Western European CMO usage by segment, 2011–2017
•Conclusion
Strong growth in the emerging regions
•Summary
•Introduction
•The Eastern European CMO market
- Overview
•The Chinese CMO market
- Overview
- Chinese CMO usage by segment, 2011–2017
•The Indian CMO market
- Overview
- Indian CMO usage by segment, 2011–2017
•The Asian CMO market, exclusive of China and India
- Overview
- Other Asian CMO usage by segment, 2011–2017
•The Latin American CRO market
- Overview
- Latin American CMO usage by segment, 2011–2017
•Conclusion The emerging global markets for pharmaceutical contract manufacturing are growing quickly, fueled by sponsors' desire to reduce costs while improving manufacturing efficiencies. Each region, however, is subject to varying drivers and restraints based upon its own economy, demographics, legal and regulatory system/s, infrastructure, patent laws and other issues. While India and China are known for their high growth, other regions including Eastern Europe, Other Asian countries and La
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |